• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Studies Find Keytruda Effective Against 3 Cancer Types

Article

One of the hot new cancer immunotherapy drugs, Merck & Co's Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to 3 studies presented at the American Association for Cancer Research conference.

One of the hot new cancer immunotherapy drugs, Merck & Co's Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to 3 studies presented Sunday at the American Association for Cancer Research conference in Philadelphia.

One study, comparing Keytruda to Bristol-Myers Squibb Co's Yervoy, could give Merck a temporary advantage as the rivals battle for market supremacy and billions of dollars in annual sales from this new generation of drugs, which help the immune system destroy cancer cells. While research continues, the pace is quickening and big improvements in patient care regimens are likely fairly soon.

Read more from the Associated Press and ABC News: http://abcn.ws/1D8z4z3

Related Videos
5 experts are featured in this series.
5 experts are featured in this series.
Chelsee Jensen, PharmD, BCPS.
5 experts are featured in this series
1 expert is featured in this series.
5 experts are featured in this series
5 experts are featured in this series.
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.